PNC-27
A chimeric anticancer peptide that selectively kills cancer cells by binding to HDM-2 on their membranes, inducing pore formation and necrosis while leaving normal cells unharmed.
What is PNC-27?
PNC-27 is a chimeric peptide with two functional domains: an HDM-2-binding region derived from the tumor suppressor p53 (residues 12-26) and a cell-penetrating domain (penetratin). It was designed to exploit a key difference between cancer and normal cells — cancer cells express the oncogenic protein HDM-2 (human double minute 2, also called MDM2) on their cell surface membranes, while normal cells do not. PNC-27 binds to this membrane-bound HDM-2, forms pores in the cancer cell membrane, and induces necrotic cell death. The selectivity has been demonstrated across multiple cancer types — pancreatic, breast, ovarian, cervical, and leukemia — while leaving normal cells of the same tissue type unharmed. Published in PNAS and studied for over 15 years, PNC-27 remains preclinical but represents one of the more mechanistically elegant approaches to targeted cancer cell killing.
Why People Talk About It
Selective cancer cell killing (spares normal cells)
PreliminaryActivity across multiple cancer types
PreliminaryWorks independently of p53 status (kills p53-deleted cancers)
PreliminarySynergy with chemotherapy (paclitaxel)
PreliminaryDual mechanism: membrane pore formation + mitochondrial disruption
LimitedHow It Works
PNC-27 is like a guided missile for cancer cells. Cancer cells have a specific protein (HDM-2) on their surface that normal cells don't. PNC-27 locks onto this protein using a piece borrowed from p53 (the "guardian of the genome"), then punches holes in the cancer cell membrane, causing it to burst. Normal cells without surface HDM-2 are invisible to PNC-27.
Common Questions
Safety Information
Common Side Effects
Cautions
- • No human clinical trials — all data is in vitro
- • Not available for clinical use
- • In vitro selectivity does not guarantee in vivo safety
- • Gray market sources should be treated with extreme caution for any research peptide claiming anticancer properties
What We Don't Know
All data is from cell culture experiments. Whether PNC-27's selectivity for cancer cells translates to in vivo animal models and ultimately humans is unknown. Pharmacokinetics, biodistribution, off-target effects, and immune responses have not been characterized in living organisms. The IC50 of 12.4 μM in cervical cancer suggests relatively high doses may be needed.
Published Research
9 studiesHDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for diagnostics and treatment of cancer.
PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane.
The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide.
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
Related Peptides
Quick Facts
- Class
- Anticancer Peptide
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 9PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.